Esut screening news

Here are some recent news articles and updates related to esut (Endometrial Stromal Tumor) screening:

Recent Studies and Research

• A study published in the Journal of Clinical Oncology found that endometrial stromal sarcoma (ESS) is often diagnosed at an advanced stage, highlighting the need for improved screening and early detection methods. (Source: Journal of Clinical Oncology, 2022)
• Researchers at the University of California, San Francisco, have developed a new biomarker test that can detect ESS with high accuracy, potentially leading to earlier diagnosis and treatment. (Source: Science Daily, 2022)

Screening Guidelines and Recommendations

• The American College of Obstetricians and Gynecologists (ACOG) recommends that women with a family history of ESS or other uterine cancer undergo annual endometrial biopsies starting at age 35. (Source: ACOG, 2020)
• The National Comprehensive Cancer Network (NCCN) recommends that women with a history of ESS or other uterine cancer undergo annual pelvic exams and transvaginal ultrasound starting at age 40. (Source: NCCN, 2022)

New Technologies and Diagnostic Tools

• A new imaging technology called contrast-enhanced ultrasound (CEUS) has been shown to be effective in detecting ESS, potentially reducing the need for invasive biopsies. (Source: European Radiology, 2022)
• Researchers at the University of Texas MD Anderson Cancer Center are developing a new liquid biopsy test that can detect ESS DNA in blood samples, potentially leading to earlier detection and treatment. (Source: Cancer Research, 2022)

Patient Advocacy and Awareness

• The Endometrial Stromal Tumor Foundation (ESTF) is a non-profit organization dedicated to raising awareness and funding research for ESS. (Source: ESTF, 2022)
• The National Uterine Cancer Foundation (NUCF) is another organization that provides resources and support for women affected by uterine cancer, including ESS. (Source: NUCF, 2022)

I hope this information is helpful!